Overview

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.

Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.

Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.

Recent News
Jun 6, 2024

—Ex Vivo Studies Using Clinical Samples from Patients with Liver Fibrosis Reinforce the Anti-Fibrotic Activity of CM-101 by Showing the Drug’s Direct Interference with Liver Fibroblast...

May 17, 2024

TEL AVIV, Israel ─ May 17, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

May 9, 2024

─On Track for Midyear 2024 Topline Data and Late 2024/Early 2025 Open Label Data Readouts from CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis (PSC), Following Early Completion of Patient...

May 8, 2024

TEL AVIV, Israel ─ May 8, 2024 ─ Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases...

All News

Stock Info
NASDAQCMMB
Events
Wednesday, June 5, 2024 - Saturday, June 8, 2024

Date: June 6, 2024
Time: 8:30-18:00 CEST
Format: Poster presentation: Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101
Presenter: Revital Aricha, PhD, Vice President, Translational Science, Chemomab Therapeutics
Session: Poster - Fibrosis/Stellate cell biology, Abstract #380

Date: June 6, 2024
Time: 8:30-17:00 CEST
Format: Poster presentation: Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score
Presenter: Ilan Vaknin, PhD, Vice President, R&D, Chemomab Therapeutics
Session: Immune-mediated and cholestatic: Experimental and pathophysiology, Abstract #1032

Date: June 7, 2024
Time: 12:25-13:45 CEST
Format:  Poster Tour: Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101
Presenter: Ilan Vaknin, PhD, Vice President, R&D, Chemomab Therapeutics
Session: Fibrosis/Stellate Cell Biology Poster Tour, Abstract #380
Location: Basic Science Track Hub
Information: EASL Congress 2024

Monday, June 3, 2024 - Thursday, June 6, 2024

Date: June 3-6, 2024
Format:  One-on-One Partnering Meetings
Location:  San Diego Convention Center
Information: Click here

All Events

Featured Presentations

Download

Chemomab Corporate Overview - June 2024